Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin expression
Sari M. Sillanpää
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Search for more papers by this authorMaarit A. Anttila
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorKirsi A. Voutilainen
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Search for more papers by this authorKirsi M. Ropponen
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorReijo K. Sironen
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorSerpo V. Saarikoski
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorCorresponding Author
Veli-Matti Kosma
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland
Fax: +358-17-162-753
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, FinlandSearch for more papers by this authorSari M. Sillanpää
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Search for more papers by this authorMaarit A. Anttila
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorKirsi A. Voutilainen
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Search for more papers by this authorKirsi M. Ropponen
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorReijo K. Sironen
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorSerpo V. Saarikoski
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland
Search for more papers by this authorCorresponding Author
Veli-Matti Kosma
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland
Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland
Fax: +358-17-162-753
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, FinlandSearch for more papers by this authorAbstract
We investigated the expression and prognostic significance of matrix metalloproteinase (MMP) -7, its relation to β-catenin expression and clinicopathological factors in epithelial ovarian cancer. The expression of MMP-7 was analyzed immunohistochemically in a series of 284 primary epithelial ovarian cancers, their 36 metastases and 8 normal ovaries. In cancers with endometrioid histology, a high percentage area of MMP-7 expression and an intense MMP-7 signal was significantly associated with nuclear positivity of β-catenin in cancer cells (p = 0.003, χ2 = 8.853 and p = 0.030, χ2 = 4.713, respectively). In all tumors and nonendometrioid subgroup, a low percentage area of MMP-7 positive tumor cells was significantly correlated with a high histological grade of the tumor (p = 0.003 and 0.005, respectively), in all tumors also with advanced stage of the tumor (p = 0.002) and large primary residual tumor (p = 0.005). A 10-year disease-related survival (DRS) was significantly better when the percentage area of MMP-7 expression in cancer cells was high, when compared to low (p = 0.0008). A high percentage area of intense MMP-7 signal in cancer cells predicted a significantly more favorable DRS and recurrence-free survival (RFS) (p = 0.0003 and 0.0052, respectively). In multivariate analysis, a high percentage area of intense MMP-7 signal in tumor cells was an independent prognostic factor, predicting favorable DRS and RFS. The present study showed that intense MMP-7 signal in tumor cells is an independent prognostic factor predicting better survival in epithelial ovarian cancer. © 2006 Wiley-Liss, Inc.
References
- 1 Sudbeck BD, Pilcher BK, Welgus HG, Parks WC. Induction and repression of collagenase-1 by keratinocytes is controlled by distinct components of different extracellular matrix compartments. J Biol Chem 1997; 272: 22103–10.
- 2 Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, Sato H, Seiki M. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 1995; 72: 311–22.
- 3 Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411–22.
- 4 Birkedal-Hansen H. Matrix metalloproteinases. Adv Dent Res 1995; 9: 16.
- 5 Katrib A, Tak PP, Bertouch JV, Cuello C, McNeil HP, Smeets TJ, Kraan MC, Youssef PP. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 988–94.
- 6 Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621–30.
- 7
Curran S,
Murray GI.
Matrix metalloproteinases in tumour invasion and metastasis.
J Pathol
1999;
189:
300–8.
10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C CAS PubMed Web of Science® Google Scholar
- 8 Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996; 28: 123–36.
- 9 Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003; 22: 145–52.
- 10 Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 2005; 114: 19–31.
- 11 Shigemasa K, Tanimoto H, Sakata K, Nagai N, Parmley TH, Ohama K, O'Brien TJ. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol 2000; 17: 52–8.
- 12 Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, Clarke J, O'Brien TJ. The matrix metalloprotease pump-1 (MMP-7, matrilysin): a candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999; 20: 88–98.
- 13
Yamashita K,
Azumano I,
Mai M,
Okada Y.
Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis.
Int J Cancer
1998;
79:
187–94.
10.1002/(SICI)1097-0215(19980417)79:2<187::AID-IJC15>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 14 Zeng ZS, Shu WP, Cohen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002; 8: 144–8.
- 15 Nelson WJ, Nusse R. Convergence of wnt, β-catenin, and cadherin pathways. Science 2004; 303: 1483–7.
- 16 Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O, Clevers H. XTcf-3 transcription factor mediates β-catenin-induced axis formation in xenopus embryos. Cell 1996; 86: 391–9.
- 17 Kolligs FT, Bommer G, Goke B. Wnt/β-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 2002; 66: 131–44.
- 18 Zhai Y, Wu R, Schwartz DR, Darrah D, Reed H, Kolligs FT, Nieman MT, Fearon ER, Cho KR. Role of β-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas. Am J Pathol 2002; 160: 1229–38.
- 19 Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155: 1033–8.
- 20 Saeki H, Tanaka S, Sugimachi K, Kimura Y, Miyazaki M, Ohga T, Sugimachi K. Interrelation between expression of matrix metalloproteinase 7 and β-catenin in esophageal cancer. Dig Dis Sci 2002; 47: 2738–42.
- 21 Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000; 60: 150–5.
- 22 Bohm J, Niskanen L, Kiraly K, Kellokoski J, Eskelinen M, Hollmen S, Alhava E, Kosma VM. Expression and prognostic value of α-, β-, and γ -catenins indifferentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 4806–11.
- 23 Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A. E-cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol 2000; 79: 362–71.
- 24 Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. β-Catenin expression pattern in stage I and II ovarian carcinomas: relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155: 527–36.
- 25 Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001; 61: 8247–55.
- 26 Catasus L, Bussaglia E, Rodrguez I, Gallardo A, Pons C, Irving JA, Prat J. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of β-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360–8.
- 27 Palacios J, Catasus L, Moreno-Bueno G, Matias-Guiu X, Prat J, Gamallo C. β- and γ-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001; 438: 464–9.
- 28 Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998; 16: 577–85.
- 29 Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, Nakatani Y, Kimura S, Kitajima H, Koshikawa N, Miyazaki K, Kitamura H. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997; 28: 613–22.
- 30
Adachi Y,
Yamamoto H,
Itoh F,
Arimura Y,
Nishi M,
Endo T,
Imai K.
Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers.
Int J Cancer
2001;
95:
290–4.
10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- 31 Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, Atomi Y. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001; 84: 1317–21.
- 32 Liu XP, Kawauchi S, Oga A, Tsushimi K, Tsushimi M, Furuya T, Sasaki K. Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma. Jpn JCancer Res 2002; 93: 291–5.
- 33 Yamashita K, Mori M, Shiraishi T, Shibuta K, Sugimachi K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000; 6: 1169–74.
- 34 Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999; 59: 3313–6.
- 35 Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K, Miwa K, Sugiyama K, Sasaki T. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer 2000; 3: 63–70.
- 36 Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001; 19: 1118–27.
- 37 Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004; 10: 2832–45.
- 38 Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, Okita K. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003; 89: 2116–21.
- 39 Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997; 272: 28823–5.
- 40 DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 2004; 164: 1131–9.
- 41 Mylona E, Kapranou A, Mavrommatis J, Markaki S, Keramopoulos A, Nakopoulou L. The multifunctional role of the immunohistochemical expression of MMP-7 in invasive breast cancer. APMIS 2005; 113: 246–55.
Citing Literature
